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ABSTRACT
EFFECTS OF BERBERINE ON DEVELOPMENT IN CAENORHABDITIS
ELEGANS
SEPTEMBER 2020
ZHUOJIA QIAN, B.E., HUAZHONG AGRICULTURAL UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Yeonhwa Park

Berberine is an isoquinoline alkaloid found in some plants and has many
bioactivities including anti-microbial, lipid- and glucose-lowering, anti-cancer,
anti-inﬂammatory, etc. However, there is limited knowledge about berberine’s
effects on development and locomotive activity. Herein, in vivo studies were
conducted to determine these effects of berberine using Caenorhabditis elegans as
an in vivo model. Treatment of berberine at 50 μM starting at L1 stage significantly
retarded the growth rate of nematodes, and reduced the length, width and moving
speed of worms by 19%, 12% and 29%, respectively, compared to the control. In
addition, triglycerides (TG) and protein content in worms was reduced by 23% and
28%, respectively, after berberine treatment from L1 stage compared with the
control group. However, no significance was observed when berberine was treated
from young adult stage. These findings suggest that berberine has effects on
development in C. elegans.
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CHAPTER 1
INTRODUCTION

Berberine is an isoquinoline alkaloid found in several plants such as Berberis
vulgaris (barberry), Berberis aristata (tree turmeric), and Coptis chinensis (Chinese
goldthread)1. There are also dietary supplements containing berberine processed
from these plants. It has been proven that berberine has health benefits, including
anti-microbial, lipid- and glucose-lowering, anti-cancer, anti-inﬂammatory,
reducing cardiovascular diseases, and improving nervous system, etc2–10. There are
limited reports of the effects of berberine on locomotion, including its protective
role for morphine-, cocaine- and ethanol-induced adverse effects and its stimulation
effects on locomotor activity in Drosophila melanogaster11–15. However, studies on
the effects of berberine on growth and locomotive activity, especially in vivo studies,
are still inadequate.
Caenorhabditis elegans is a small free-living nematode found in temperate
soil environments, which has been widely applied in many scientific researches
focusing on obesity, aging, and development16–19. This animal model has many
advantages, such as a small body size, short life span, large brood size, and low
maintenance cost20. In addition to its rapid life cycle20, every stage in its life cycle
has easily distinguishable features20. Locomotion behavior of C. elegans, as an
indicator of activity, can be measured with a tracking system21. Furthermore, it has
many development- and locomotion-related genes, which are orthologs of human
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genes21–24. Thus, C. elegans was utilized as an in vivo model in the current study to
investigate the effects of berberine on growth and locomotion.
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CHAPTER 2
LITERATURE REVIEW

2.1 Caenorhabditis elegans
2.1.1 Introduction
C. elegans is a small free-living nematode found in temperate soil environments
worldwide16,17. It was first introduced as a genetic model to study developmental
biology and neurobiology by Sydney Brenne in 1960s16,17. C. elegans is now widely
applied in research involving obesity, aging, development, locomotion behavior,
and neurodegenerative disorders19,25.
Compared with traditional animal models, this eukaryotic and multi-organ
animal model possesses many advantages. It has a small body size, short life span,
and large brood size20. At the same time, C. elegans is inexpensive and convenient
to maintain20. Furthermore, it has a completely sequenced and well-annotated
genome, which encodes over 65% of characterized human disease-related genes25.
Moreover, it has many mutants available, which could be easily utilized for
mechanistic studies26. And research using C. elegans does not require approval
from the Institutional Animal Care and Use Committees25.

2.1.2 Life Cycle
The life cycle of C. elegans consists of four larval stages (L1, L2, L3, and L4 stage)
and adulthood27. C. elegans embryogenesis takes around 16 hours at 20 oC. L1
larvae are hatched out from eggs and take around another 16 hours to develop into
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the L2 stage. L2, L3 and L4 stages last around 12 hours long, respectively20. Each
stage ends with a period called lethargus, during which a new cuticle of nematodes
is made28. Lethargus ends with molting of the old cuticle. Approximately 12 hours
after molting of nematodes at the L4 stage20, C. elegans at adulthood begins to
produce progeny, which will last 5-6 days. However, when L2 larvae lack food or
are crowded, they will develop into an alternative life cycle29 and molt into an
alternative L3 stage called the “dauer” stage30. At this stage, the dauer larvae have
enhanced resistance against environmental stresses, can survive for several months,
and continue to develop as slightly different L4 larvae if they are provided with
enough food20.

2.1.3 Locomotion Behavior
There are 302 neurons of 959 somatic cells in nematodes. C. elegans shares highly
conserved neurotransmitter receptors, neurotransmitter synthesis and release
pathways, heterotrimeric guanosine-5'-triphosphate (GTP) binding proteins
coupled second messenger pathways, and major genes involved with mammals23,31.
Therefore, this animal model has been widely applied in research to study basic
mechanisms underlying drug-induced behaviors by investigating its locomotion
behavior23,24. 75 motoneurons of 302 neurons control body wall muscles, which
provide thrust for C. elegans during locomotion32. The regular contraction and
relaxation of muscle cells innervated by motoneurons in C. elegans lead to its
movement20,32.
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C. elegans locomotes in an undulatory way33,34. It generates thrust by
propagating the bending of its body in the direction of locomotion34. When
nematodes move on the surface of the agar, the routes they crawled through will
produce typical S shapes. Without the consideration of steering, the locomotion
behavior of C. elegans could be generally divided into four patterns: forward
locomotion, backward locomotion, dwelling (nondirectional body bends), and
quiescence28,35–37. Each of these patterns could appear randomly and persist for a
while during nematodes’ locomotion38–40. Such locomotion behavior can be
recorded and analyzed with a tracking system21.

2.1.4 Uptake of Compounds into C. elegans
C. elegans is actively utilized as a research model to determine activities of various
compounds. There are mainly three ways to deliver compounds to C. elegans: [1]
mix compounds with nematodes’ bacterial food source, [2] directly spread
compounds onto the surface of nematode growth medium (NGM) agar plates, and
[3] add compounds into nematodes’ liquid medium41. However, it is worth noting
that the ﬁnal concentration of dimethyl sulfoxide (DMSO) solution in nematodes’
medium higher than 0.6% (v/v) will shorten the life span of C. elegans42.
Compounds can be taken up by C. elegans via three ways: ingestion,
through the cuticle, and exposed sensory neuronal cilia43. During ingestion,
appropriate food sources will be recognized and chosen by chemosensory neurons
and then consumed via aspiration by pharynx of C. elegans. Then compounds will
be absorbed by intestinal cells and distributed throughout the worm body43. The
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cuticle of C. elegans can also allow diffusion of some compounds into and out of
nematodes through a permeability barrier established by hypodermis44. Lastly,
compounds may be directly taken up via exposed sensory neuronal cilia of
nematodes45.

2.2 Berberine
2.2.1 Introduction
Berberine is an isoquinoline alkaloid found in plants such as Berberis vulgaris
(barberry), Berberis aristata (tree turmeric), and Coptis chinensis (Chinese
goldthread)1. The main biological properties of berberine reported are antimicrobial, lipid- and glucose-lowering, anti-cancer, and anti-inﬂammatory
effects1,9,46. In addition, berberine has been reported to have beneficial effects on
cardiovascular system1 and nervous system2.
There are reports of berberine’s effects at the cellular level, particularly in
hepatocytes, macrophages, endothelial cells, adipocytes, and myocytes46. Berberine
mainly protected them from the adverse effects of atherosclerosis47–50 and improved
glucose utilization in adipocytes and myocytes51.
In addition, in vivo and clinical studies of berberine have reported on its
effects on hypercholesterolemia, diabetes, and obesity46. However, based on the
evidence available to date, additional well-designed trials to confirm the safety and
efficacy of berberine are still needed46.
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2.2.2 Effects of Berberine on Cytotoxicity
Research on the cytotoxicity of berberine generally used bacterial colony and
mammalian cell lines. Several studies concluded that berberine could inhibit the
growth of different species of bacteria and change their structures3,4, which proves
that berberine has anti-microbial effects. Others reported that berberine inhibited
the growth of many cancer cells, originated from prostate5, neuroblastoma52, lung6,
cervix7, breast8, and others10. This also supports the anti-cancer properties of
berberine.

2.2.3 Effects of Berberine on Locomotion
Previously it was reported that berberine could prolong life span and stimulate
locomotor activities of Drosophila melanogaster11. In this study, the vertical
climbing assay was used to measure the ability of Drosophila to climb the wall of
a vial when startled11, assessing ability to complete a strenuous activity53. Berberine
stimulated vertical climbing of flies by 39% over the control in the climbing height
indicator11.
In addition, the effects of berberine on locomotion were investigated when
studying its inhibition of morphine-, cocaine- and ethanol-induced adverse effects.
Berberine could attenuate the expression of sensitization to locomotor stimulant
effects of morphine, cocaine, and ethanol12–15. However, research focusing on the
influence of berberine on animals’ locomotion still needs further study.
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2.2.4 Effects of Berberine on Lipid Metabolism
Berberine has been studied on its lipid-lowering effect both in cellular and animal
models50,54–60. Treatment with berberine reduced plasma total cholesterol and nonHDL (high-density lipoprotein) cholesterol levels in atherogenic diet-fed rats and
high-fat

diet-fed

mice56,57,59,60.

Oral

administration

of

berberine

in

hypercholesterolemic patients also reduced serum cholesterol, triglycerides, and
LDL (low-density lipoprotein) cholesterol levels50. Berberine also inhibited hepatic
fat accumulation in mice and attenuated hepatic steatosis in hamsters54,59. It has
been concluded that berberine acts in the liver to regulate lipid utilization54. These
ﬁndings support that berberine has therapeutic potential to treat metabolic
dysfunctions under nutritional overloads, such as fatty liver diseases and type 2
diabetes, and is suggested to be a new hypolipidemic drug.

2.2.5 The Role of AMP-activated Protein Kinase in Berberine’s Effects
A number of studies reported that the major cellular process in which berberine is
effective involves AMP-activated protein kinase (AMPK)61, which plays a critical
role in cellular energy homeostasis61. The activation of AMPK by berberine led to
its antidiabetic properties62–65. In addition, this can also demonstrate that
berberine’s potential in inhibiting aging-related diseases via AMPK cellular kinase
activation66–68. AMPK also possesses significance in physical activity69,70,
lysosomal damage, and inflammatory diseases71,72.
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2.3 Conclusion
C. elegans is a well-established in vivo model for studying the beneficial effects of
food bioactive compounds. Berberine has shown to possess anti-microbial, lipidand glucose-lowering, anti-cancer, and anti-inﬂammatory properties. However,
research on its effects on exercise and growth is not comprehensive yet. Therefore,
the goal of the current research was to determine the role of berberine on growth
and locomotive activity using C. elegans as an animal model.
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CHAPTER 3
MATERIALS AND METHODS

3.1 Materials
Berberine chloride (97%), commercial kits for triglycerides (Infinity™
Triglycerides Liquid Stable Reagent), and protein (Pierce™ BCA Protein Assay
Kit) quantification were purchased from Thermo Fisher Scientific Chemicals, Inc.
(Waltham, MA). Chemicals used for Caenorhabditis elegans maintenance
including agar, peptone, and LB broth were purchased from Fisher Scientific, Inc.
(Pittsburgh, PA). Ampicillin, carbenicillin, and fluorodeoxyuridine (FUdR) were
purchased from Sigma-Aldrich Co. (St. Louis, MO). Escherichia coli (E. coli)
OP50 and C. elegans wild isolate (N2) were obtained from Caenorhabditis Genetics
Center (Minneapolis, MN).

3.2 C. elegans Maintenance and Treatment
C. elegans was maintained as previously reported26. E. coli OP50 was prepared as
a food source. Berberine stock solutions were prepared in dimethyl sulfoxide
(≥99.9%, DMSO). For treatment starting from the L1 stage, synchronized L1 C.
elegans was treated with DMSO (0.1% v/v final) as vehicle or 50 mM berberine
stock solutions (0.1% v/v final) in S Medium for 48 hours at 20 oC. For treatment
starting from the young adulthood stage, firstly synchronized L4 C. elegans was
treated with 6 mM FUdR solution (2% v/v final). And then, worms on the first day
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of adulthood were treated with DMSO (0.1% v/v final) as vehicle or 50 mM
berberine stock solutions (0.1% v/v final) in S Medium for 48 hours at 20 oC.

3.3 Growth Rate, Body Size and Locomotive Activity Assay
For the growth rate assay, numbers of C. elegans at different larval stages were
counted after 48-hour treatment. Results were presented as percentages of C.
elegans numbers at different larval stages to the total.
Body size and locomotive activity of C. elegans were measured with a
WormLab tracking system73 (MBF Bioscience, Williston, VT). C. elegans were
transferred onto a low-peptone NGM (nematode growth medium) plate freshly
seeded with E. coli OP50 solution in LB broth. The worms were allowed to move
around freely for 10 minutes and become acclimated to light for another 10 minutes
before recording. Each video recording of C. elegans for 1 minute was analyzed
with a WormLab software (MBF Bioscience version 3.1.0, Williston, VT) for
average moving speed, worm length, and worm width.

3.4 Triglyceride and Protein Quantification
After the 48-hour treatment, C. elegans was collected and washed five times with
Milli-Q water to eliminate E. coli and berberine. C. elegans was then dissolved in
Tween 20 (0.05% v/v), sonicated, and measured for triglycerides (TG) and protein
content with the commercial kits as described before73. Protein content was used to
normalize TG levels.
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3.5 Statistical Analysis
Statistical analysis was performed through Chi-square (and Fisher’s exact) test and
t-tests (and nonparametric tests) using GraphPad Prism (GraphPad Software
version 8.4.2, San Diego, CA) or one-way ANOVA (Tukey’s test for multiple
comparisons) using Statistical Analysis System (SAS Institute version 9.4, Cary,
NC). Differences between groups were considered significant at p < 0.05.
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CHAPTER 4
RESULTS

4.1 Berberine Inhibited Growth of Caenorhabditis elegans
There were 91% of the worms at the L4 stage, 3% at the L3 stage, 5% at the L2
stage, and 1% at the L1 stage in the control group after 48 hours of incubation
(Figure 4.1). However, only 67% of the worms reached the L4 stage, 19% at the L3
stage and 14% at the L2 stage in the 50 μM berberine group. This suggests that the
growth rate was significantly slowed after 48 hours of treatment of berberine at 50
μM compared to the control (p = 0.0001).

Figure 4.1 Berberine significantly slowed the growth rate of C. elegans.
Synchronized L1 worms were treated with control (0.1% DMSO) or berberine (50
μM) for 48 hours at 20 oC. The growth rate was scored as percentages of worms’
numbers at different developmental stages to the total. Results are presented as
means ± S.E. (n = 4 plates, each plate contained ≈ 50 worms). a, b Means with
different letters are significantly different (p < 0.05).
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4.2 Effects of Berberine on Body Size and Locomotive Activity
When berberine was treated from L1 stage, the length of worms was significantly
decreased by 19% compared to the control (p < 0.0001, Figure 4.2A). Similarly,
the width of the worms in the 50 μM berberine treated group was also decreased
significantly by 12% compared with the control group (p < 0.0001, Figure 4.2B).
These are consistent to the result of retarded growth rate by berberine in Figure 4.1.

Figure 4.2 Effects of berberine treatment during development on body size
and locomotive activity of C. elegans. Synchronized L1 worms were treated with
control (0.1% DMSO) or berberine (50 μM) for 48 hours at 20 oC. Body size,
including worm length (A) and width (B), and locomotive activity, presented as
average moving speed (C), were measured with the WormLab tracking system.
Results are presented as means ± S.E. (n = 350-400 worms). a, b Means with
different letters are significantly different (p < 0.05).
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Treatment of 50 μM berberine significantly reduced the moving speed of
the worms by 29% compared to the control (p < 0.0001, Figure 4.2C), which may
also be due to the retarded growth rate by the berberine treatment. Taken together,
it is suggested that both the body size and moving speed of worms were
significantly reduced after 48 hours of treatment of berberine at 50 μM.

Figure 4.3 Effects of berberine on body size and locomotive activity treated
from young adulthood in C. elegans. Synchronized worms on the first day of
adulthood were treated with control (0.1% DMSO) or berberine (50 μM) for 48
hours at 20 oC. Body size, including worm length (A) and width (B), and
locomotive activity, presented as average moving speed (C), were measured with
the WormLab tracking system. Results are presented as means ± S.E. (n = 40-80
worms).

Next, we treated berberine after nematodes were fully grown. There was no
significant difference in worm length between worms of the control and berberine
groups (Figure 4.3A). However, there was a significant reduction of body width by
15

berberine treatment over the control, 6% reduction with p = 0.0199 (Figure 4.3B).
This suggests that berberine has small, but significant effects on body size of C.
elegans at the young adulthood stage. There was no difference in moving speed
between treatments (Figure 4.3C).

4.3 Effects of Berberine on Triglycerides and Protein Content
The triglycerides (TG) level in worms treated with 50 μM berberine from L1 stage
was significantly reduced by 23% compared with the control group (p = 0.0004,
Figure 4.4A). Similarly, the content of protein was also significantly reduced by
berberine treatment, 28%, compared to the control (p < 0.0001, Figure 4.4B). The
lower level of the TG and protein by berberine treatment seen in Figure 4.4 may be
due to the retarded growth rate in C. elegans74,75.

Figure 4.4 Effects of berberine on triglycerides (TG, A) and protein (B) content
treated from L1 stage in C. elegans. Synchronized L1 worms were treated with
control (0.1% DMSO) or berberine (50 μM) for 48 hours at 20 oC. TG content was
measured and normalized by protein levels. Results are presented as means ± S.E.
(n = 5 plates, each plate contained ~ 1,000 worms). a, b Means with different letters
are significantly different (p < 0.05).
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When nematodes were treated with berberine from young adulthood, there
was no significant difference in TG content between control and berberine groups
(Figure 4.5). And no significant difference was observed in protein levels between
two groups as well. This suggests that berberine has no effect on fat accumulation
in C. elegans.

Figure 4.5 Effects of berberine on triglycerides (TG) content treated from
young adulthood in C. elegans. Synchronized worms on the first day of adulthood
were treated with control (0.1% DMSO) or berberine (50 μM) for 48 hours at 20
o
C. TG content was measured and normalized by protein levels. Results are
presented as means ± S.E. (n = 6 plates, each plate contained ~ 1,000 worms).
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CHAPTER 5
DISCUSSION

Berberine, an isoquinoline alkaloid found in several plants, has been reported to
have many beneficial effects1,2,9,46. In the current study, treatment of berberine
during growth period significantly retarded the growth of Caenorhabditis elegans,
accompanied with reduced body size, reduced moving speed, and reduced both
triglycerides (TG) and protein content of worms, while no significant effects were
observed when berberine was treated after worms were fully grown.
Normally, L1 larvae will take around 40 hours to develop into the L4 stage.
When facing unfavorable environmental condition, larvae of nematodes at the L2
stage can arrest development themselves by forming dauer larvae29,30. In addition,
C. elegans larvae were reported to be able to reversibly arrest development at the
L1 stage, which was called “L1 arrest”76. These are two kinds of naturally occurring
growth inhibition without any treatment, which are similar to the results observed
in the current study.
The most direct reason for the above two phenomena is the starvation of
worms29,30,76. High density and temperature are also common reasons for dauer
arrest76. As for our study, because worms of both the control and treatment groups
were provided with almost the same nematode density and temperature, one of the
possible reasons is that berberine suppressed the worms’ food intake.
What’s more, insulin-like signaling, phosphatase and tensin homolog
(PTEN), liver kinase B1 (LKB1), AMPK, and fatty acid biosynthesis in C. elegans
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have already been reported to be involved in development22,76. It was reported that
reduced insulin-like signaling would induce developmental quiescence77. At the
same time, AMPK would interact with insulin-like signaling76,78. In C. elegans,
mutation of aak-2, which is a homologue of AMPK and evolutionarily conserved
in both C. elegans and mammals79, was proved to result in an L1 arrest-defective
phenotype76,80. Besides, C. elegans orthologues of LKB1 and AMPK could
cooperate to establish cell cycle quiescence in the germline stem cell population as
well when insulin-like signaling was reduced22. Combined with the reports that
AMPK is critical in many properties of berberine mentioned before61, AMPK could
also play an important role in the retarded growth rate caused by berberine here.
Accompanied with the retarded growth rate, worms’ body size, moving
speed, and both TG and protein content were reduced after treatment of berberine.
The reduction of body size was consistent with the developmental delay in C.
elegans. And it is known that worms deposit TG after they are grown18,81. Thus, the
lower TG content was accompanied with retarded growth rate. In addition, the
lower level of protein in worms may be due to the influence of berberine on the
metabolic activities in C. elegans74,75.
One previous study using Drosophila melanogaster as a model reported the
stimulation effects of berberine on locomotor activities11. However, we did not
observe any significant changes of activity by berberine treatment, which means
that 50 μM berberine cannot stimulate locomotive activity in C. elegans. It is
possible that the dosage of berberine treated in this study was lower than the
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Drosophila study (1 mM)11. Higher doses of berberine could be utilized to conduct
locomotive activity studies in C. elegans in the future.
Berberine has been reported to have lipid-lowering effect54,56,57,59,60.
However, the reduction of TG content in the current study was observed when
berberine was treated during worms’ growth period only, but not after worms were
fully grown. Based on our preliminary experiment using fat models (worms treated
with glucose from L4 stage) of C. elegans82, berberine still have no effect on TG
content. In addition, berberine at higher concentration (100, 200, and 300 μM)
significantly reduced protein content without changing the TG content. This
suggests that berberine has no effect on lipid metabolism in this model. Possible
reasons may be the different stages of the life cycle of nematodes used in this study
and the comparatively lower dosage of berberine treated compared to other in vivo
studies54,56,57,59,60.
To conclude, the current results suggest the inhibitory effect of berberine on
the growth of C. elegans. Its body size and moving speed were significantly reduced
when berberine was treated during worms’ growth period. This is the first study to
demonstrate the influence of berberine on the development of C. elegans, which
could provide important information and foundation for future studies of berberine.
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CHAPTER 6
FUTURE RESEARCH

In this current research, berberine has effects in C. elegans on development as seen
in growth rate, body size, locomotion, protein, and triglycerides. However, the
mechanisms of these effects have not been determined. Further researches could be
conducted to provide more comprehensive evidence for berberine’s effects.
To complement current research, future work could be carried out from
three aspects. First, the food intake assay of C. elegans at the L1 stage treated by
berberine could be conducted. This could be one possible reason leading to the
retard growth rate29,30,76. Secondly, AMPK is a potential critical pathway of
berberine’s effects on development of C. elegans22,61,76, thus using different
mutants with gene knocked out26, such as aak-2 (homolog of AMPK), can be
utilized to determine its effects. Lastly, the effects of berberine at higher doses,
particularly on the locomotive activity in C. elegans, need to be determined.
In conclusion, the current research showed that berberine could
significantly delay the development in C. elegans. These findings could provide
important foundation for future studies of berberine.
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